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Abstract
The tumour microenvironment (TME) is recognised as an important prognostic characteristic and therapeutic
target in patients with colorectal cancer (CRC). However, assessment generally utilises surgically resected speci-
mens, precluding neoadjuvant targeting. The present study investigated the feasibility of intra-epithelial CD3+
T-lymphocyte density and tumour stroma percentage (TSP) assessment using preoperative colonoscopic biopsies
from 115 patients who had undergone resection of stages I–III CRC, examining the relationship between biopsy
and surgically resected specimen-based assessment, and the relationship with cancer-speciﬁc survival (CSS). High
biopsy CD3+ density was associated with high CD3+ density in the invasive margin, cancer stroma and intra-
epithelial compartments of surgically resected specimens (area under the curve > 0.62, p < 0.05 for all) and with
high Immunoscore. High biopsy TSP predicted high TSP in resected specimens (p = 0.001). Intra-class correlation
coefﬁcient for both measures was >0.7 (p < 0.001), indicating excellent concordance between individuals. Biopsy
CD3+ density (hazard ratio [HR] 0.23, p = 0.002) and TSP (HR 2.23, p = 0.029) were independently associated
with CSS; this was comparable to the prognostic value of full section assessment (HR 0.21, p = 0.004, and HR
2.25, p = 0.033 respectively). These results suggest that assessment of the TME is comparable in biopsy and sur-
gically resected specimens from patients with CRC, and biopsy-based assessment could allow for stratiﬁcation
prior to surgery or commencement of therapy targeting the TME.
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Introduction
The prognosis of colorectal cancer and the need for
adjuvant therapy are determined by pathological
staging according to IUCC/AJCC TNM staging
criteria. However, such staging is suboptimal, par-
ticularly given that increasing disease stage may not
necessarily reﬂect increasing risk of cancer-
associated mortality [1]. As such, there has been a
concerted effort over the past decades to identify
both molecular and pathological characteristics that
may determine both prognosis and need for additional
treatment.
Tumour microenvironment characteristics are impor-
tant determinants of disease progression and survival.
A pronounced local inﬂammatory cell inﬁltrate is syn-
onymous with good prognosis across a number of
solid organ cancers, with numerous scores based upon
this premise described in patients with colorectal can-
cer [2–4]. Of these, the Immunoscore©, a measure of
CD3+ and CD8+ T-lymphocyte density, has recently
been internationally validated as a stage-independent
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predictor of survival in stages I–III disease [4]. Simi-
larly, other components of the tumour microenviron-
ment, such as the tumour-associated stroma [5], hold
additional and complementary prognostic value when
examined in combination with the inﬂammatory cell
inﬁltrate [6,7].
In addition to determining prognosis, the tumour
microenvironment may also aid in determining non-
surgical treatment of patients with colorectal cancer.
Both the local immune response and the tumour-
associated stroma moderate response to chemotherapy
and radiotherapy [8–13]. Furthermore, the tumour
microenvironment may be a potential target for novel
therapies, such as immune checkpoint blockade and
TGF-β inhibition, in its own right [14–16].
However, one limitation of the use of the tumour
microenvironment to guide treatment is that methods
described to date have generally relied on comprehen-
sive assessment of the surgically resected specimen.
Although aiding in the determination of prognosis, this
limits the potential for selection of preoperative neo-
adjuvant therapies based upon tumour microenviron-
ment characteristics. Furthermore, it also precludes the
use of such measures to inform prognosis of patients
with metastatic or locally advanced disease not amena-
ble to surgical resection, as well as those with com-
plete pathological response following neoadjuvant
treatment.
One potential strategy to assess the tumour microen-
vironment prior to surgery is the use of preoperative
endoscopic biopsies. Several groups have characterised
the local inﬂammatory cell inﬁltrate in this manner,
with a view to determining treatment-related changes in
immune cell inﬁltrates and predicting response to
chemoradiotherapy in patients with rectal cancer
[8–12,17,18]. However, to date only three small studies
(examining 31, 54 and 50 patients, respectively) have
compared the local inﬂammatory cell inﬁltrate in biop-
sies and fully resected surgical specimens of patients
without intervening neoadjuvant chemoradiotherapy
[9,10,19]. Furthermore, although previously examined
in patients with oesophageal cancer [20], the feasibility
of biopsy-based assessment of the tumour stroma in
patients with colorectal cancer remains to be fully deter-
mined. Therefore, whether biopsy-based assessment of
tumour microenvironment characteristics is directly
comparable to surgically resected specimens, and whether
such measures may also determine prognosis, remains
to be determined.
The aim of the present study was to examine the
feasibility of assessment of the tumour inﬂammatory
cell inﬁltrate and stroma using endoscopy biopsy spec-
imens in a cohort of patients undergoing potentially
curative resection of stages I–III colorectal cancer
without prior neoadjuvant therapy.
Materials and methods
Patients
Patients who had undergone resection of stages I–III
colorectal cancer in Glasgow Royal Inﬁrmary between
1997 and 2005, and in whom the tumour microenvi-
ronment had been characterised as part of a previous
study [21], were included. Only patients who had
undergone colonoscopy and biopsy with pathological
conﬁrmation of invasive colorectal adenocarcinoma
within the biopsy specimen were included. Patients
without biopsy evidence of invasion, who had received
neoadjuvant chemoradiotherapy prior to surgery, or
who underwent localised excision only were excluded.
Tumours were staged using the ﬁfth edition of the
tumour, node and metastases (TNM) classiﬁcation,
consistent with practice current in the United Kingdom
during the study period [22]. Patients were followed-
up for 5 years following surgery. Date and cause of
death was crosschecked with the cancer registration
system and the Registrar General (Scotland), with
death records complete until 15 March 2013 that
served as censor date. Cancer-speciﬁc survival was
measured from surgery until date of death from meta-
static or recurrent colorectal cancer. The local institu-
tional ethics committee approved the study.
Assessment of tumour microenvironment
Surgically resected specimens
Using full sections from the surgically resected speci-
men, the density of mature (CD3+) and cytotoxic
(CD8+) T-lymphocytes within the invasive margin,
cancer epithelium and stroma was semi-quantitatively
assessed at ×100 total magniﬁcation as absent or low
(low), or moderate or high (high) as previously
described [21]. Assessment was based on a generalised
overview of the full stained section rather than individ-
ual regions. The invasive margin was deﬁned as ‘the
interface between the host stroma and the invading
edge are of a tumour’, excluding intra-epithelial lym-
phocytes at the invasive edge, consistent with prior
work by Klintrup et al [3]. A composite immune-
inﬁltrate score, composed of density of CD3+ and
CD8+ T-lymphocytes within the invasive margin and
intra-epithelial compartments, was calculated ranging
from Im0 (both low in both regions) to Im4 (both high
in both regions).
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The tumour-associated stroma was assessed using
tumour stroma percentage (TSP) as previously
described [13]. In brief, using H&E-stained sections of
the deepest point of invasion, the area of intra-
tumoural stroma was graded as low (≤50%) or
high (>50%).
Biopsy specimens
Formalin-ﬁxed parafﬁn-embedded blocks and H&E-
stained sections of endoscopic biopsy specimens
taken at time of diagnosis were used. Sections 2.5 μm
thick were cut and mounted on silanised slides before
being dewaxed and rehydrated through graded alco-
hol. An autostainer (ThermoFisher Autostainer 480s)
was used to perform staining. Antigen retrieval was
carried out in a PT module (Thermo Fisher, Waltham,
MA, USA) using ThermoFisher dewax/retrieve solu-
tion pH 9. Primary antibody (CD3+; 9107S, Thermo-
Fisher) was applied for 20 min (1:100 dilution) at
room temperature following antigen retrieval. Signal
was ampliﬁed and visualised using the ThermoFisher
Quanto kit and the diaminobenzidine (DAB) colour
developer. Sections were converted to digital format
using a Hamamatsu Nanozoomer (Welwyn Garden City,
Hertfordshire, UK) at ×20 objective magniﬁcation, and
visualisation performed using Slidepath Digital Image
Hub, version 4.0.1 (Slidepath, Leica Biosystems, Milton
Keynes, UK).
At ×200 total magniﬁcation, a maximum of three
0.6 mm × 0.6 mm (total area 0.36 mm2) high-power
ﬁelds (HPF) most representative of the whole
section were identiﬁed, and the number of intra-
epithelial CD3+ T-lymphocytes within each HPF coun-
ted and an average calculated. Areas of dysplastic or
normal mucosa were excluded, as were T-lymphocytes
outside the epithelial compartment. This method was
chosen as it was assumed to be comparable to the use
of a tissue microarray, where assessment of three cores
(0.6 mm diameter) has been considered comparable to
full section analysis [23].
Assessment of TSP using H&E-stained biopsy sec-
tions was performed similarly to Courrech Staal et al
[20]. At ×100 total magniﬁcation, the proportion of
intra-tumoural stroma was graded as low (≤50%) or
high (>50%). Assessment was performed in regions
where tumour cells were present circumferentially,
with mucinous deposits, necrosis and dysplastic or
normal mucosa, or stromal fragments without any can-
cer cells, excluded. Both biopsy T-lymphocyte and
TSP were scored by a single examiner blinded to
clinicopathological data (JHP), with independent
co-scoring of each by a blinded examiner (HvW and
CSDR, respectively). Inter-observer variability was
examined using intra-class correlation coefﬁcient.
Examples of biopsy CD3+ T-lymphocyte staining and
TSP assessment are displayed in Figure 1.
Statistical analysis
The relationship between biopsy intra-epithelial CD3+
T-lymphocyte count and T-lymphocyte density within
the invasive margin, cancer stroma and intra-epithelial
compartment of full, surgically resected specimens
was examined using Mann–Whitney U-test and area
under the curve (AUC) to identify optimal threshold
for low/high density within biopsy specimens. Chi-
square analysis for linear trend was subsequently used
to compare tumour microenvironment characteristics
in biopsy and surgically resected specimens.
To further examine clinical utility of biopsy-based
assessment of the tumour microenvironment, the rela-
tionship with cancer-speciﬁc survival was examined.
Univariate Cox regression analysis was subsequently
performed to calculate hazard ratios (HRs) and 95%
CI. To assess whether biopsy assessment had compa-
rable prognostic value to conventional, full-section
assessment, two multivariate models were created
alongside other clinicopathological characteristics
using a backwards stepwise method; the ﬁrst model
included biopsy intra-epithelial CD3+ density and
TSP, whereas the second model included assessment
of CD3+ density and TSP using surgically resected
specimens. Kaplan–Meier curves and log-rank analysis
were used to compare difference between groups.
A P value ≤0.05 was considered statistically signiﬁcant.
All analyses were performed using SPSS version 22.0
for Mac (Armonk, NY, USA).
Results
Matched biopsy and surgically resected specimens of
120 patients who underwent potentially curative re-
section of stages I–III colorectal cancer were retrieved.
Five patients did not have adequate biopsy tissue for
CD3+ staining, resulting in 115 patients being included
in the study; clinicopathological characteristics are dis-
played in Table 1. About 91 patients (79%) had sufﬁ-
cient biopsy material to examine three HPFs; of the
remaining patients, 12 had sufﬁcient material for
examination of two HPFs, and 12 for examination of
one ﬁeld. Mismatch repair status was available for
91 patients; 9 patients (10%) were MMR deﬁcient.
The intra-class correlation coefﬁcient for assessment
of biopsy intra-epithelial CD3+ density and TSP were
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0.866 and 0.743, respectively (both p < 0.001), indi-
cating excellent concordance.
The median biopsy intra-epithelial CD3+ T-
lymphocyte count was 24 cells/HPF (interquartile
range [IQR] 16–36, range 4–183). Tumours with a
high CD3+ density within the invasive margin, stroma
and intra-epithelial compartments of the surgically
resected specimen had a higher biopsy T-lymphocyte
count (all p < 0.05, Table 2). Receiving operating
characteristic and AUC was used to determine thresh-
old for biopsy CD3+ T-lymphocyte count (Table 2,
and see supplementary material, Figure S1); the
optimal cut-off for predicting high density within each
region was identical and corresponded with the median
(low <25 cells/HPF; high ≥25 cells/HPF). Biopsy den-
sity was most predictive of intra-epithelial CD3+ den-
sity, with a sensitivity and speciﬁcity of 79 and 70%,
and positive and negative predictive value of 57 and
87% (see supplementary material, Table S1). In addi-
tion to being associated with invasive margin, stromal
and intra-epithelial CD3+ density, high biopsy intra-
epithelial CD3+ density was also associated with intra-
epithelial CD8+ density and the combined CD3+/CD8+
assessment (both p < 0.001), and showed a trend
Figure 1. Examples of matched biopsy-based and full section-based assessments of the tumour microenvironment in patients with colo-
rectal cancer (×200 total magniﬁcation). Panels A and B respectively display a biopsy specimen with high intra-epithelial CD3+ density
(122 cells/high powered ﬁeld) and corresponding full section with high intra-epithelial and stromal CD3+ density. Both specimens also
display a low tumour stroma percentage. Panels C and D respectively display a biopsy specimen with low intra-epithelial CD3+ density
(9 cells/high powered ﬁeld) and corresponding full section with low intra-epithelial and stromal CD3+ density. Panels E and F display
matched biopsy and full haematoxylin and eosin-stained sections with high tumour stroma percentage.
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towards an association with invasive margin and stro-
mal CD8+ density (p = 0.07 and p = 0.058 respec-
tively; Table 3).
Biopsy assessment of TSP was examined (Table 3)
and found to be associated with full section assessment
(p = 0.001). Although the negative predictive value of
biopsy-based assessment was high, the positive predic-
tive value was low (90 and 38% respectively; see sup-
plementary material, Table S1).
About 4 patients (44%) with MMR deﬁcient cancer
each had a high biopsy intra-epithelial CD3+ density
and biopsy TSP compared to 35 (43%) and 28 (34%)
of patients with MMR competent colorectal cancer
respectively. The small number of patients with MMR
deﬁcient colorectal cancer precluded meaningful statis-
tical analysis of the relationship between MMR status
and tumour microenvironment characteristics.
Median follow-up of survivors was 136 months
(range 89–193) with 33 cancer and 32 non-cancer
deaths. On univariate survival analysis, a high biopsy
intra-epithelial CD3+ density was associated with
improved survival (HR 0.21, 95% CI 0.09–0.52,
p = 0.001) whereas a high biopsy TSP was associated
with reduced survival (HR 2.78, 95% CI 1.39–5.54,
p = 0.004). The effect on survival was comparable to
assessment of CD3+ density and TSP using surgically
resected specimens (HR 0.22, 95% CI 0.08–0.64,
p = 0.005, and HR 2.41, 95% CI 1.17–4.98, p = 0.018).
On multivariate analysis (Table 4), biopsy CD3+ den-
sity (HR 0.23, p = 0.002) and biopsy TSP (HR 2.23,
p = 0.029) were associated with survival independent
of TNM stage, venous invasion and margin involve-
ment. This was again comparable to the prognostic
value of assessment using surgically resected speci-
mens (see supplementary material, Table S2).
Table 1. Clinicopathological characteristics of patients with
primary operable colorectal cancer (n = 115)
Clinicopathological characteristics
(n when data missing)
Patients
(%)
Age
<65 43 (37)
65–74 36 (31)
>74 36 (31)
Sex
Male 61 (53)
Female 54 (47)
Adjuvant therapy
No 80 (70)
Yes 35 (30)
Tumour site
Colon 78 (68)
Rectum 37 (32)
TNM stage
I 6 (5)
II 52 (45)
III 57 (50)
T stage
1–2 12 (10)
3 73 (64)
4 30 (26)
N stage
0 58 (50)
1 45 (39)
2 12 (11)
Differentiation
Mod-well 110 (96)
Poor 5 (4)
Venous invasion
Absent 78 (68)
Present 37 (32)
Margin involvement
Absent 110 (96)
Present 5 (4)
Peritoneal involvement
Absent 85 (74)
Present 30 (26)
Tumour perforation
Absent 113 (98)
Present 2 (2)
Mismatch repair status (n = 91)
Competent 82 (90)
Deﬁcient 9 (10)
CD3+ margin density (n = 114)
Low 61 (53)
High 53 (47)
CD3+ stroma density
Low 52 (45)
High 63 (55)
CD3+ cancer cell nest
Low 77 (67)
High 38 (33)
CD8 margin density (n = 107)
Low 59 (55)
High 48 (45)
(Continues)
Table 1. Continued
Clinicopathological characteristics
(n when data missing)
Patients
(%)
CD8 stroma density (n = 110)
Low 76 (69)
High 34 (31)
CD8 cancer cell nest (n = 110)
Low 75 (65)
High 35 (30)
Immune cell density (n = 107)
0 37 (35)
1–2 41 (38)
3 17 (16)
4 12 (11)
Tumour stroma percentage
Low 90 (78)
High 25 (22)
5Preoperative TME assessment in colorectal cancer
© 2019 The Authors. The Journal of Pathology: Clinical Research published by The Pathological
Society of Great Britain and Ireland and John Wiley & Sons Ltd.
J Pathol Clin Res 2019
The Glasgow Microenvironment Score (GMS), com-
posed of assessment of the local inﬂammatory cell inﬁl-
trate and TSP, has been shown to have greater
prognostic value than either measure alone in patients
with colorectal cancer [21,22]. As such, the feasibility of
a biopsy-based GMS (bGMS) was examined, and
devised as follows: bGMS0 – high biopsy intra-epithelial
CD3+ density; bGMS1 – low biopsy intra-epithelial
CD3+ density and low biopsy TSP; bGMS2 – low
biopsy intra-epithelial CD3+ density and high biopsy
TSP. This score was similar to full section assessment of
the GMS in this cohort (Figure 2), and stratiﬁed survival
of patients into three prognostic groups with ﬁve-year
survival of 92% (n = 53), 76% (n = 34) and 51%
(n = 28), respectively (p < 0.001).
The biopsy specimens of patients in which there
was a discrepancy between biopsy and full
section intra-epithelial CD3+ density were further
examined (see supplementary material, Table S3).
Seven patients were incorrectly classiﬁed as having
low CD3+ density on the basis of biopsy assessment;
of these, three biopsy specimens were fragmented and
had small surface area, and two were of small foci of
invasive cancer within adenoma or normal mucosa.
The remaining two specimens showed no evident
issues, suggesting that technical factors accounted for
incorrect classiﬁcation in ﬁve of seven cases. A total
of 23 patients were incorrectly classiﬁed as high CD3+
density on the basis of biopsies. Of those with a
biopsy CD3+ > 48 cells/HPF, only two were incor-
rectly classiﬁed as high density, with both biopsy
specimens fragmented and with small surface area. Of
the remaining 21 incorrectly classiﬁed patients, four
biopsy specimens were fragmented/had small surface
area, three had small foci of cancer within adenoma
and 14 showed no evident technical issues.
Discussion
The present study conﬁrms that preoperative, endo-
scopic biopsy-based assessment of the tumour
Table 2. Relationship between biopsy intra-epithelial CD3+ T-cell count and full section assessment of CD3+ T-cell density
Biopsy CD3+ T-cell count
Full section CD3+ T-cell density n Median CD3+ cell count (IQR, max) P value* AUC (95% CI)
115 24 (16–36; 4–183) – –
CD3+ margin 0.024 0.622 (0.519–0.726)
Low 61 22 (13–32)
High 53 27 (19–43)
CD3+ stroma 0.005 0.651 (0.549–0.753)
Low 52 20 (14–29)
High 63 27 (19–37)
CD3+ intra-epithelial <0.001 0.773 (0.674–0.872)
Low 77 20 (13–27)
High 38 34 (25–63)
*Mann–Whitney U-test.
Table 3. Relationship between biopsy and full section assessment
of the tumour microenvironment
Biopsy intra-epithelial CD3+ T-cell
density
Full section tumour
microenvironment
Low
(n = 61)
High
(n = 53)
P
value
CD3+ margin 0.045
Low 38 23
High 23 30
CD3+ stroma 0.003
Low 36 16
High 26 37
CD3+ intra-epithelial <0.001
Low 54 23
High 8 30
CD8+ margin 0.070
Low 35 24
High 20 28
CD8+ stroma 0.058
Low 44 32
High 12 21
CD8+ intra-epithelial <0.001
Low 48 27
High 9 26
Immunoscore <0.001
0 27 10
1–2 21 20
3 5 12
4 2 10
Biopsy stroma percentage
Low (n = 73) High (n = 42) P value
TSP 0.001
Low 64 26
High 9 16
Threshold: low <25 CD3+ T-lymphocytes/HPF, high ≥25 CD3+
T-lymphocytes/HPF.
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microenvironment is representative of assessment
within the surgically resected specimen and has com-
parable prognostic value. In addition to aiding in the
preoperative staging of patients with colorectal cancer,
biopsy-based assessment may also identify patients
who could potentially beneﬁt from neoadjuvant strate-
gies targeting the tumour microenvironment.
Recent interest in the molecular taxonomy of colo-
rectal cancer has directed efforts to identify molecular
subtype prior to surgery using biopsy-derived tissue
[24]. Of interest, although epithelial cell-derived sub-
types appear to be robustly predicted using biopsy
specimens, those which incorporate mesenchymal and
immune cell derived components appear to be identi-
ﬁed less reliably [24]. Therefore, it is reassuring in the
present study that biopsy intra-epithelial CD3+ density
correlated with full section assessment of the local
inﬂammatory cell inﬁltrate across a number of differ-
ent tumour regions. This is consistent with prior work
proposing correlation of immune cell densities across
different tumour subsites [21]. However, although
biopsy-assessment of TSP correlated signiﬁcantly with
full section assessment, this association was not as
robust. Indeed, this would suggest that, despite lumen-
derived biopsies being a reliable surrogate for assess-
ment of the local inﬂammatory cell inﬁltrate, they may
not as accurately predict TSP.
However, the present study relied on the use of ret-
rospective, clinical-grade biopsy specimens. Biopsy
specimens vary not only in size and tissue quality,
but also abundance of tumour tissue present [25].
Whereas the only criterion for biopsies to be included
in the present analysis was the presence of invasive
malignancy, more rigorous criteria may result in more
accurate assessment. For example, Saridaki et al
reported that stringent selection criteria for biopsy
sections (at least 20% of invasive malignancy present
in the biopsy and at least six fragments present)
increased concordance with full section analysis for
mutational analysis [26]. In the present study, it
was apparent that technical factors related to biopsy
specimen quality resulted in incorrect classiﬁcation
of patients, particularly those incorrectly classiﬁed as
having low CD3+ T-cell density. Furthermore,
biopsy specimens of sufﬁcient size to allow for at
least three HPFs to be examined increased sensitivity
and speciﬁcity (data not shown). Therefore, future
studies should ensure that sufﬁcient representative
biopsy specimens are retrieved using a standardised
approach, incorporating adequate targeting of the
tumour and retrieval of specimens of either sufﬁcient
size or quantity (e.g. three to ﬁve biopsies for optimal
tumour microenvironment assessment). In addition,
staining for additional markers may also provide
more comprehensive assessment; e.g. the addition of
CD8+ could provide a biopsy-based surrogate compa-
rable to the Immunoscore [8], whereas staining for
markers associated with tumour-associated ﬁbroblasts
may improve sensitivity and speciﬁcity of the biopsy
assessment of TSP.
Despite the above technical factors being considered,
it was of interest that 14 tumours incorrectly classiﬁed
as high CD3+ T-cell density had technically satisfactory
biopsy specimens. This may however reﬂect the semi-
quantitative nature employed for assessment of immune
cell inﬁltrates within the surgically resected specimen,
as 12 tumours had evidence of weak rather than absent
CD3+ T-cell inﬁltration. Therefore, it may be expected
that a more quantitative and objective assessment of
immune inﬁltrates within the resected specimen may
have shown closer correlation between biopsy and sur-
gically resected specimens.
Table 4. Relationship between clinicopathological characteristics, biopsy assessment of the tumour microenvironment and
cancer-speciﬁc survival
Biopsy assessment Cancer-speciﬁc survival
Clinicopathological characteristics Univariate analysis P value Multivariate analysis P value
Age (<65/65–74/>75) 1.17 (0.77–1.77) 0.471 – –
Sex (female/male) 1.41 (0.70–2.84) 0.331 – –
Adjuvant therapy (no/yes) 1.21 (0.59–2.51) 0.600 – –
Tumour site (colon/rectum) 1.74 (0.86–3.50) 0.123 – –
TNM stage (I/II/III) 2.49 (1.25–4.93) 0.009 2.24 (1.09–4.59) 0.029
Tumour differentiation (mod-well/poor) 1.50 (0.40–6.29) 0.577 – –
Venous invasion (no/yes) 3.34 (1.66–6.70) 0.001 2.22 (1.07–4.61) 0.033
Margin involvement (no/yes) 5.93 (2.05–17.11) 0.001 8.18 (2.52–26.55) <0.001
Peritoneal involvement (no/yes) 1.69 (0.83–3.44) 0.147 – –
Tumour perforation (no/yes) 3.10 (0.42–22.81) 0.266 – –
Mismatch repair status (competent/deﬁcient) 0.34 (0.05–2.49) 0.287 – –
Biopsy T-lymphocyte density (low/high) 0.21 (0.09–0.52) 0.001 0.23 (0.09–0.57) 0.002
Biopsy tumour stroma percentage (low/high) 2.78 (1.39–5.54) 0.004 2.23 (1.09–4.58) 0.029
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In addition to allowing for preoperative assessment of
the tumour microenvironment, biopsy-based assessment
was shown to have prognostic value independent of
pathological staging. Using the combination of biopsy
TSP and T-lymphocyte density alone, it was possible to
stratify ﬁve-year survival from 92% (high CD3+ den-
sity) to 51% (low CD3+ density and high TSP), strik-
ingly similar to the prognostic value of the GMS [6].
Although it is not expected that biopsy-based assess-
ment of the tumour microenvironment will replace full
section analysis following potentially curative surgery,
it may however have a role in the treatment of patients
not undergoing surgical resection. For example, it
would be of considerable interest to investigate whether
biopsy assessment of the tumour microenvironment
may stratify survival of patients with advanced, inopera-
ble colorectal cancer, and how this may subsequently
impact upon therapeutic options. Furthermore, given
recent interest in the neoadjuvant treatment of locally
advanced colon cancer [27], as well as the potential
application of total neoadjuvant therapy regimens, there
will be a need for more detailed assessment of initial
biopsy specimens in the event of complete clinical and
pathological response.
The tumour microenvironment is a viable therapeutic
target in patients with gastrointestinal cancers [28–30].
The present work provides a justiﬁcation for the use of
biopsy-derived assessments to quantify immune cell inﬁl-
trates and stromal inﬁltration on biopsies. Biopsy-derived
assessment may allow for personalisation of preoperative
treatment strategies, particularly where the tumour micro-
environment may be immune ‘cold’ or ‘altered’ [15]. For
example, in patients diagnosed with rectal cancer and
found to have a low lymphocyte density on biopsy, one
potential strategy could involve preoperative radiotherapy
to promote tumour immunogenicity and increase tumour
inﬁltration by activated immune cells [8–10], with serial
biopsies performed to evaluate subsequent response.
Taken together, it is clear that accurate biopsy-derived
assessments are key to the successful implantation of
‘window of opportunity’ trials in which novel neo-
adjuvant strategies tested prior to surgical resection are
assessed for response based on in vivo biomarkers. We
present a rationale for the use of the threshold of ≥25
cells/HPF to categorise CD3+ inﬁltrates as high or low
grade in biopsies that has the potential to be applied in
clinical studies.
The present study is limited by the lack of a valida-
tion cohort and use of a relatively historical cohort;
whether the present results are reproducible in other
cohorts and using more contemporary, targeted speci-
mens of sufﬁcient quality remains to be determined.
However, the present methodologies employed may be
readily tested and allow for validation in other cohorts
of patients with colorectal cancer.
In conclusion, the results of the present study sug-
gest that assessment and staging of the tumour micro-
environment of patients undergoing resection of
colorectal cancer is feasible using endoscopic biopsy
specimens. This simple approach will allow for appro-
priate stratiﬁcation of patients and treatment selections
on the basis of the tumour microenvironment prior to
potentially curative resection.
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